Invion

Invion Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Invion (IVX.AX) as of Oct 11, 2026 is 42.14 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 33.71 % — a change of 25.01% (higher).

Cash Conversion

42.14 %

YoY

25.01%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Invion is 2026 42.14 % . Cash Conversion Rate (OCF/Net Income) of Invion was 2025 33.71 % . It decreases by 25.01% higher compared to the previous year.

The Invion Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2019
82.70 AUD
Jan 1, 2020
15.98 AUD
Jan 1, 2021
-28.19 AUD
Jan 1, 2022
49.47 AUD
Jan 1, 2023
112.25 AUD
Jan 1, 2024
42.67 AUD
Jan 1, 2025
33.71 AUD
Jan 1, 2026
42.14 AUD
The Invion Cash Conversion history
YEARCash ConversionYoY
42.14 %+25.01%
33.71 %-21.01%
42.67 %-61.99%
112.25 %+126.89%
49.47 %-275.53%
-28.19 %-276.34%
15.98 %-80.67%
82.70 %-208.36%
-76.32 %-779.29%
11.23 %-86.96%
86.16 %+10.91%
77.69 %+22.83%
63.25 %—
Access this data via the Eulerpool API

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

Cash Conversion Rate (OCF/Net Income) of Invion is 42.14 % in 2026.

Cash Conversion Rate (OCF/Net Income) of Invion changed from 33.71 % to 42.14 %, representing a 25.01% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Invion since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Invion with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

Cash Flow — Invion

All Key Metrics — Invion